JPH052648B2 - - Google Patents
Info
- Publication number
- JPH052648B2 JPH052648B2 JP31228087A JP31228087A JPH052648B2 JP H052648 B2 JPH052648 B2 JP H052648B2 JP 31228087 A JP31228087 A JP 31228087A JP 31228087 A JP31228087 A JP 31228087A JP H052648 B2 JPH052648 B2 JP H052648B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hepatitis
- virus
- present
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 24
- 229940127009 HBV antigen inhibitor Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 description 7
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- -1 oral preparation Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000122 inhibitory effect on hepatitis Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31228087A JPH01153637A (ja) | 1987-12-11 | 1987-12-11 | B型肝炎ウイルス抑制剤 |
IL86381A IL86381A0 (en) | 1987-05-19 | 1988-05-15 | Oxetanocins and pharmaceutical compositions containing the same |
DE3851179T DE3851179T2 (de) | 1987-05-19 | 1988-05-17 | Oxetanocin. |
EP88107852A EP0291917B1 (en) | 1987-05-19 | 1988-05-17 | Novel oxetanocins |
AT88107852T ATE110382T1 (de) | 1987-05-19 | 1988-05-17 | Oxetanocin. |
DK271388A DK271388A (da) | 1987-05-19 | 1988-05-18 | Oxetanocinereller farmakologisk acceptable salte deraf samt deres anvendelse |
AU16398/88A AU599232B2 (en) | 1987-05-19 | 1988-05-18 | Novel oxetanocins |
KR1019880005757A KR880013937A (ko) | 1987-05-19 | 1988-05-18 | 옥세타노신 유도체 |
CA000567114A CA1304365C (en) | 1987-05-19 | 1988-05-18 | Oxetanocins |
HU882537A HUT47128A (en) | 1987-05-19 | 1988-05-19 | Process for producing oxetanocins and pharmaceutical compositions comprising such compounds |
CN88102932A CN1017153B (zh) | 1987-05-19 | 1988-05-19 | 嘌呤取代的氧杂环丁烷类化合物的制备方法 |
US07/439,270 US5214048A (en) | 1987-05-19 | 1989-11-20 | Oxetanocins |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31228087A JPH01153637A (ja) | 1987-12-11 | 1987-12-11 | B型肝炎ウイルス抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01153637A JPH01153637A (ja) | 1989-06-15 |
JPH052648B2 true JPH052648B2 (zh) | 1993-01-13 |
Family
ID=18027341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP31228087A Granted JPH01153637A (ja) | 1987-05-19 | 1987-12-11 | B型肝炎ウイルス抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01153637A (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59102422D1 (de) * | 1990-10-19 | 1994-09-08 | Basf Ag | Ungesättigte Cyclohexenonoximether. |
EP1685127A1 (en) * | 2003-11-21 | 2006-08-02 | The University of Connecticut | Heterocyclyl-substituted oxetanes for the treatment of proliferative or infectious diseases |
-
1987
- 1987-12-11 JP JP31228087A patent/JPH01153637A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH01153637A (ja) | 1989-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69922529T2 (de) | Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten | |
US20030004119A1 (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
TW202146011A (zh) | 治療b型肝炎病毒感染之組合療法 | |
JPH052648B2 (zh) | ||
EP0290817B1 (en) | A use of oxetanocin for inhibiting hiv | |
CN1447692A (zh) | 药物释放至肝细胞和治疗黄病毒感染的方法 | |
JPH04234320A (ja) | 抗hbv剤 | |
JPH05331061A (ja) | アポトーシス誘起剤 | |
EP4056565A1 (en) | Liver targeting drug, pharmaceutical composition and use thereof | |
JP5061352B2 (ja) | 肝臓疾患治療剤及び肝機能改善剤 | |
US6245813B1 (en) | Use of ubenimex and the pharmaceutical composition containing it for treating virus hepatitis | |
JP2002535371A (ja) | リバビリンによる免疫応答の調節 | |
JPS63284129A (ja) | B型肝炎ウイルス抑制剤 | |
JPH11209282A (ja) | ベルゲニン及びその誘導体を有効成分とする肝機能改善剤 | |
JP3064027B2 (ja) | 血管新生阻害剤 | |
JPH0132826B2 (zh) | ||
JPH06206822A (ja) | B型肝炎ウイルス抑制剤 | |
JPH0616561A (ja) | 抗レトロウイルス剤 | |
JP2001039868A (ja) | 抗ウイルス製剤および該製剤を用いたウイルス感染症予防・治療方法 | |
JP2799368B2 (ja) | 抗原虫剤 | |
JPH02221220A (ja) | 骨髄異形成症候群治療剤 | |
JPH04234319A (ja) | 抗hbv剤 | |
JP2004518618A (ja) | 疾患の治療における改善特異性 | |
JPH01117830A (ja) | 抗サイトメガロウイルス剤 | |
CN114478709A (zh) | 一种长效肝炎病毒进入抑制剂 |